Dextrose
Prescription商品名: DEXTROSE
About This Medication
DESCRIPTION Each 100 mL of 5% Dextrose Injection USP contains: Hydrous Dextrose USP 5 g; Water for Injection USP qs pH: 4.4 (3.5–6.5); Calculated Osmolarity: 250 mOsmol/liter Calories per liter: 170 Each 100 mL of 10% Dextrose Injection USP contains: Hydrous Dextrose USP 10 g; Water for Injection USP qs pH: 4.4 (3.5–6.5); Calculated Osmolarity: 505 mOsmol/liter, hypertonic Calories per liter: 340 Dextrose Injections USP are sterile, nonpyrogenic and contain no bacteriostatic or antimicrobial agents. These products are intended for intravenous administration. The formula of the active ingredient is: Ingredient Molecular Formula Molecular Weight Hydrous Dextrose USP 198.17 Not made with natural rubber latex, PVC or DEHP. The plastic container is made from a multilayered film specifically developed for parenteral drugs. It contains no plasticizers and exhibits virtually no leachables. The solution contact layer is a rubberized copolymer of ethylene and propylene. The container is nontoxic and biologically inert. The container-solution unit is a closed system and is not dependent upon entry of external air during administration. The container is overwrapped to provide protection from the physical environment and to provide an additional moisture barrier when necessary. Addition of medication should be accomplished using complete aseptic technique. The closure system has two ports; the one for the administration set has a tamper evident plastic protector and the other is a medication addition site. Refer to the Directions for Use of the container. Chemical Structure
有効成分
| 成分 | 含有量 |
|---|---|
| Dextrose, Unspecified Form | - |
適応症と用法
用量と投与方法
Side Effects Overview
警告と注意事項
WARNINGS The administration of intravenous solutions can cause fluid and/or solute overload resulting in dilution of serum electrolyte concentrations, overhydration, congested states or pulmonary edema. The risk of dilutional states is inversely proportional to the electrolyte concentration. WARNING: Dextrose Injection USP contains aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which contain aluminum. Research indicates that patients with impaired kidney function, including premature neonates, who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration. Prolonged infusion of isotonic or hypotonic dextrose in water may increase the volume of extracellular fluid and cause water intoxication. Solutions containing dextrose without electrolytes should not be administered simultaneously with blood through the same infusion set because of the possibility of agglomeration. Excessive administration of potassium-free dextrose solutions may result in significant hypokalemia. Serum potassium levels should be maintained and potassium supplemented as required. In very low birth weight infants, excessive or rapid administration of dextrose injection may result in increased serum osmolality and possible intracerebral hemorrhage.
禁忌
CONTRAINDICATIONS Solutions containing dextrose may be contraindicated in patients with hypersensitivity to corn products.
Frequently Asked Questions
INDICATIONS AND USAGE These intravenous solutions are indicated for use in adults and pediatric patients as sources of calories and water for hydration.
DOSAGE AND ADMINISTRATION These solutions are for intravenous use only. Dosage is to be directed by a physician and is dependent upon age, weight, clinical condition of the patient and laboratory determinations. Frequent laboratory determinations and clinical evaluation are essential to monitor changes in blood glucose and electrolyte concentrations, and fluid and electrolyte balance during prolonged parenteral therapy. When a hypertonic solution is to be administered peripherally, it should be slowly infused through a small bore needle, placed well within …
WARNINGS The administration of intravenous solutions can cause fluid and/or solute overload resulting in dilution of serum electrolyte concentrations, overhydration, congested states or pulmonary edema. The risk of dilutional states is inversely proportional to the electrolyte concentration. WARNING: Dextrose Injection USP contains aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and …
CONTRAINDICATIONS Solutions containing dextrose may be contraindicated in patients with hypersensitivity to corn products.
Dextrose is a prescription medication. You will need a valid prescription from a licensed healthcare provider.
Similar Injection Products
Browse all Injection products →References & Data Sources
- • DailyMed — Dextrose drug label (National Library of Medicine)
- • openFDA — Dextrose label data (U.S. Food & Drug Administration)
- • RxNorm — RXCUI 1795477 (NLM Normalized Drug Names)
- • NDC Directory — Dextrose (FDA National Drug Code)
医療免責事項
このページの情報は教育目的のみを意図しており、専門家による医療アドバイス、診断、または治療の代替として使用すべきではありません。
疾患や医薬品に関するご質問がある場合は、必ず担当医またはその他の資格を持つ医療専門家にご相談ください。
データソース: DailyMed (NLM), openFDA, MFDS